Kadcyla Approved for Treatment of HER2-positive Metastatic Breast Cancers

SAN FRANCISCO – The FDA has approved Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin┬« (trastuzumab) and a taxane chemotherapy. Kadcyla is the fourth medicine from Genentech to receive FDA approval for people with advanced cancers within the past two years. An antibody-drug conjugate (ADC), Kadcyla is the first FDA-approved ADC for treating HER2-positive mBC. Kadcyla is made up of the antibody, trastuzumab, and the chemotherapy, DM1, joined together using a stable linker. Kadcyla combines the mechanisms of action of both trastuzumab and DM1, and it is the first Genentech ADC approved by the FDA.

Share Your Thoughts



Please answer the following math problem to prove you are a human! *